Eli Lilly and Co (LLY) Holdings Reduced by Private Advisor Group LLC

Private Advisor Group LLC reduced its position in Eli Lilly and Co (NYSE:LLY) by 31.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 50,399 shares of the company’s stock after selling 23,122 shares during the period. Private Advisor Group LLC’s holdings in Eli Lilly and were worth $4,331,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. Beach Investment Management LLC. purchased a new stake in Eli Lilly and in the 2nd quarter worth approximately $400,000. Federated Investors Inc. PA grew its stake in shares of Eli Lilly and by 11.0% during the 2nd quarter. Federated Investors Inc. PA now owns 229,704 shares of the company’s stock valued at $18,904,000 after buying an additional 22,811 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Eli Lilly and by 1.9% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,905,130 shares of the company’s stock valued at $239,092,000 after buying an additional 54,878 shares during the period. MUFG Americas Holdings Corp grew its stake in shares of Eli Lilly and by 29.0% during the 2nd quarter. MUFG Americas Holdings Corp now owns 166,226 shares of the company’s stock valued at $13,680,000 after buying an additional 37,407 shares during the period. Finally, Lincoln National Corp grew its stake in shares of Eli Lilly and by 16.0% during the 2nd quarter. Lincoln National Corp now owns 3,811 shares of the company’s stock valued at $313,000 after buying an additional 525 shares during the period. 76.20% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the sale, the insider now directly owns 4,130 shares of the company’s stock, valued at approximately $334,901.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the sale, the senior vice president now directly owns 124,522 shares of the company’s stock, valued at $10,766,172.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is owned by corporate insiders.

Shares of Eli Lilly and Co (LLY) opened at $76.21 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 12-month low of $73.69 and a 12-month high of $89.09. The firm has a market cap of $83,958.50, a price-to-earnings ratio of 17.82, a P/E/G ratio of 1.42 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The firm had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. During the same period in the prior year, the company earned $0.95 EPS. The firm’s revenue was up 7.0% on a year-over-year basis. analysts anticipate that Eli Lilly and Co will post 4.88 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 2.95%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is -1,039.95%.

Several analysts have recently issued reports on LLY shares. Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Goldman Sachs Group cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and boosted their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 5th. Finally, Bank of America lowered their price objective on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, February 1st. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $92.02.

WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/02/14/eli-lilly-and-co-lly-holdings-reduced-by-private-advisor-group-llc.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply